A carregar...
Progression pattern and adverse events with bevacizumab in glioblastoma
BACKGROUND: The use of bevacizumab in the management of glioblastoma multiforme (gbm) remains controversial. In Canada, bevacizumab is approved for the treatment of recurrent gbm. We describe a pattern of progression across treatment lines in gbm. METHODS: During 2008–2014, 64 patients diagnosed wit...
Na minha lista:
| Publicado no: | Curr Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Multimed Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5081019/ https://ncbi.nlm.nih.gov/pubmed/27803607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.23.3108 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|